Catalog No.
DHB86907
Host species
Homo sapiens
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
3.43 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB, Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P00533 & P08581
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, JNJ-61186372, JNJ-6372, CNTO-4424, JNJ 61186372, JNJ-611, CAS: 2171511-58-1
Note
For research use only. Not suitable for clinical or therapeutic use.
1, Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC，Doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15.
2, Amivantamab: First Approval， Doi: 10.1007/s40265-021-01561-7.
3, Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). DOI: 10.1200/JCO.2020.38.15_suppl.9512
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC, PMID: 32414908
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis, PMID: 32747419
Development of [ 89 Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer, PMID: 32770372
Antibodies to watch in 2021, PMID: 33459118
Amivantamab-vmjw, PMID: 34219152
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins, PMID: 32979839
Amivantamab: First Approval, PMID: 34292533
Amivantamab, PMID: 34165943
Amivantamab OK'd for EGFR-Mutant NSCLC, PMID: 34083225
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET, PMID: 33839159
Amivantamab Is Active in Platinum-Resistant EGFR ex20-mutant NSCLC, PMID: 34389637
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells, PMID: 27786612
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions, PMID: 34381206
Amivantamab: Treating EGFR Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation, PMID: 34339261
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study, PMID: 34339292
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations, PMID: 34285620
Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions, PMID: 34284994
Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance, PMID: 28830985
For research use only. Not for human or drug use.
